ReviewInternational journal of molecular sciences2026
From Aryltetralin Anticancer Scaffolds to Host-Directed Bioactivities: A Mechanism-Based Review of Lignans and Neolignans.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Lignans and related neolignans are a diverse class of phenolic natural products with broad biological activities and great potential for pharmaceutical applications. This article summarizes representative subclasses of lignans and compares their antitumor and antioxidant properties from a structural and mechanistic perspective. Aryltetrahydronaphthalene lignans, represented by podophyllotoxin and its semi-synthetic derivatives, provide the clearest baseline for their mechanism of action by disrupting microtubules and inhibiting topoisomerase II. Other subclasses, including dibenzylbutyrolactone, arylnaphthalene, dibenzocyclooctadiene, furofuran lignans, glycosides, and bisphenolic neolignans, exhibit anticancer and redox-regulating effects. Future research should focus on linking structural diversity with validated molecular targets, pharmacokinetic properties, and in vivo efficacy to better define their translational potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.